Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fusion protein or fusion polypeptide
Patent
1996-06-27
1999-04-20
Adams, Donald E.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Fusion protein or fusion polypeptide
4242181, 4241851, 530350, A61K 3900, A61K 3912
Patent
active
058956514
ABSTRACT:
A recombinant fusion protein (DEN-2 MBP) containing the B domain of the due (DEN 2 envelope protein is disclosed as a candidate subunit immunogen for vaccination against dengue virus infection. A gene fragment encoding amino acid 298 to amino acid 400 of the DEN-2 virus envelope was expressed as a fusion protein with the maltose binding protein (MBP) of Escherichia coli (E. coli). The recombinant fusion protein was purified and analyzed for its antigenicity imunogenicity and ability to protect mice against lethal challenge. This antigen is detected by monoclonal antibody (3H5) which is specific for a neutralizing epitope on the DEN-2 envelope and reacted with homologous polyclonal mouse immune ascitic fluid and DEN-2 immune human sera. A recombinant fusion plasmid bearing the DEN-2 MBP DNA sequence, expressing the fusion product in E. coli is disclosed. The fusion protein when administered to a host elicits a virus neutralizing antibody response which confers partial protection to the recipient animals against challenge infection. Sera from immunized mice revealed no neutralizing antibodies to any of the other DEN serotypes in the plaque reduction neutralization assay (PRNT).
REFERENCES:
patent: 5494671 (1996-02-01), Lai et al.
Mason et al., 1990, J. Gen. Virol. 71:2107-2114.
Makino et al., 1991, Am. J. Trop. Med. Hyg. 45:636-643.
Megret et al., 1992, Virol. 187:480-491.
Stanley et al., 1995, Vaccine 13:947-951.
Stephenson, J., 1988, Vaccine 6:471-480.
Kurane et al., 1992, Sem. Immunol. 4:121-127.
Smucny et al., 1995, Am. J. Trop. Med. Hyg. 53:432-437.
Morens et al., 1990, J. Gen. Virol. 71:2909-2914.
Hayes Curtis G.
Porter Kevin R.
Simmons Monika
Adams Donald E.
Parkin Jeffrey S.
Spevack, Esq. A. D.
The United States of America as represented by the Secretary of
LandOfFree
Recombinant dengue virus envelope protein/maltose-binding protei does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant dengue virus envelope protein/maltose-binding protei, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant dengue virus envelope protein/maltose-binding protei will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2246512